Stay up-to-date with our latest news and company announcements.

January 2, 2024

Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors

Enavate Sciences joins Cormorant Asset Management, Pontifax Venture Capital and Ovid Therapeutics in supporting Graviton’s development of ROCK2 inhibitors across multiple indications New York, NY, January 2, 2024 — Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) announced completion of financing from Enavate…

December 20, 2023

Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in Class TYK2 Therapeutics Programs into the Clinic

Funding to advance potential first- and best-in-class brain-penetrant TYK2 candidate in multiple sclerosis and potential first- and best-in-class topical dermal TYK2 candidate in psoriasis into the clinic. Top-tier life science investor syndicate co-led by Enavate Sciences and TPG, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, Eventide Asset Management and existing…

November 7, 2023

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBio MENLO PARK, Calif. – November 7, 2023 – OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the successful completion of a $60 million Series A financing, bringing the…

October 3, 2023

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026* Expected to submit three investigational new drug applications (INDs) within 18 months Seattle, WA, and Exton, PA October…

June 29, 2023

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125…

June 8, 2023

Upstream Bio Announces $200M Series B Financing to Advance UPB-101
for Allergic and Inflammatory Diseases

Funds to support future development of UPB-101 in asthma and CRSwNP Financing led by Enavate Sciences and Venrock Healthcare Capital Partners Bain Capital Life Sciences and Wellington Management join the syndicate WALTHAM, Mass. – June 8, 2023 – Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of…

November 10, 2022

Edd Fleming, M.D., former Senior Partner at McKinsey and Company, joins Enavate Sciences as Executive Vice President, Commercialization

MENLO PARK, Calif., November 10, 2022— Enavate Sciences, a portfolio company of Patient Square Capital, is pleased to announce that H. Edward (Edd) Fleming, Jr, M.D. has joined the firm as Executive Vice President, Commercialization. Dr. Fleming reports to James Boylan, Chief Executive Officer of Enavate Sciences, and will augment Enavate’s capabilities in the origination,…

November 7, 2022

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Proceeds to fund global Phase 3 registration program for the company’s lead product candidate, Obexelimab, and support the clinical development of other pipeline programs Series B equity financing led by Enavate Sciences, a portfolio company of Patient Square Capital, also included new investors Longitude Capital and Vivo Capital WALTHAM, Mass, November 7, 2022 (GLOBE NEWSWIRE)…

November 2, 2022

Compass Therapeutics Announces $80 Million Private Placement

BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) – Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 25,000,000 shares of its common stock…

July 20, 2022

CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic

Proceeds to Support Clinical Development of Lead CNS & Liver Programs;  IND for Dravet Syndrome is Anticipated by Mid-2023  New Capital Will Also Fuel Expansion of CAMP4’s RNA Actuating Platform™, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression  Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square Capital; Enavate CEO Jim…

Page 1 of 2